Advertisement
News
Advertisement

Ariad seeks approval for leukemia drug in Europe

Thu, 08/30/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) of Cambridge has submitted its lead compound, ponatinib, which targets a rare form of leukemia, for approval in Europe.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading